Nanostructured Lipid Carriers- A Versatile Carrier for Oral Delivery of Lipophilic Drugs

Author(s): Priyanshi Patel, Mitali Patel*

Journal Name: Recent Patents on Nanotechnology

Volume 15 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Around 40% of newly discovered chemical entities in pharmaceutical industries have poor water solubility and hence they suffer from low oral bioavailability owing to undesirable physicochemical and pharmacokinetic properties. So, it is the challenge for the formulation scientists to develop the oral formulation that can mitigate the pitfalls associated with such lipophilic drugs.

Methods: Lipid nanoparticles hold a promising tool to decrease the pitfalls of lipophilic drugs as lipid components can effectively increase the absorption of drugs, which leads to improvement in oral bioavailability. They are also considered as safe because they are made up of physiological lipids, which are biocompatible and biodegradable in nature. Amongst the lipid nanoparticles, Nanostructured Lipid Carriers (NLCs) are the second-generation lipid nanoparticles and were developed to conquer the limitations of solid lipid nanoparticles. They increase the solubility, permeability, reduce metabolism, P-glycoprotein efflux, and thereby increase the bioavailability of poorly soluble drugs.

Conclusion: This review highlights the various aspects of NLCs, such as structural components, types, in vivo fate, pharmacokinetic, toxicity, recent applications, and patent reviews of NLCs in drug delivery.

Keywords: In vivo fate, lyophilization, nanostructured lipid carrier, oral delivery, patents, pharmacokinetic, toxicity.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2021
Published on: 09 September, 2020
Page: [154 - 164]
Pages: 11
DOI: 10.2174/1872210514666200909154959
Price: $65

Article Metrics

PDF: 138